0 CHECKOUT

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015

  • ID: 3429800
  • August 2015
  • 92 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acacia Pharma Limited
  • Astellas Pharma Inc.
  • Heron Therapeutics, Inc.
  • Merck & Co., Inc.
  • SoluBest Ltd.
  • Teikoku Pharma USA, Inc.
  • MORE

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015

Summary

The report ‘Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy Induced Nausea and Vomiting’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acacia Pharma Limited
  • Astellas Pharma Inc.
  • Heron Therapeutics, Inc.
  • Merck & Co., Inc.
  • SoluBest Ltd.
  • Teikoku Pharma USA, Inc.
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Chemotherapy Induced Nausea and Vomiting Overview

Therapeutics Development

Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Overview

Pipeline Products for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis

Chemotherapy Induced Nausea and Vomiting - Therapeutics under Development by Companies

Chemotherapy Induced Nausea and Vomiting - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Chemotherapy Induced Nausea and Vomiting - Products under Development by Companies

Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development

Acacia Pharma Limited

Aphios Corporation

Astellas Pharma Inc.

Helsinn Healthcare S.A.

Heron Therapeutics, Inc.

INSYS Therapeutics, Inc.

Kyowa Hakko Kirin Co., Ltd.

Merck & Co., Inc.

RedHill Biopharma Ltd.

SoluBest Ltd.

Suda Ltd

Teikoku Pharma USA, Inc.

Tesaro, Inc.

Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(netupitant + palonosetron hydrochloride) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

APD-403 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism of Action

R&D Progress

aprepitant - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FK-886 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

granisetron ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

granisetron hydrochloride ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

netupitant - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rolapitant hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TPW-146 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Chemotherapy Induced Nausea and Vomiting - Recent Pipeline Updates

Chemotherapy Induced Nausea and Vomiting - Dormant Projects

Chemotherapy Induced Nausea and Vomiting - Discontinued Products

Chemotherapy Induced Nausea and Vomiting - Product Development Milestones

Featured News & Press Releases

Aug 17, 2015: Insys Therapeutics' Dronabinol Oral Solution NDA Accepted for Filing by FDA

Jul 20, 2015: Heron Therapeutics Resubmits SUSTOL New Drug Application to FDA

Jun 29, 2015: Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Jun 25, 2015: TESARO Announces Six Abstracts To Be Presented At The 2015 Multinational Association Of Supportive Care In Cancer Annual Meeting

Jun 02, 2015: The European Commission Approves Helsinn's Akynzeo for the Prevention of Chemotherapy Induced Nausea and Vomiting in the European Union

Jun 02, 2015: Insys Therapeutics Submits NDA for Dronabinol Oral Solution

Jun 01, 2015: New cancer therapy study results - MAGIC Trial

May 30, 2015: TESARO Announces Successful Completion of Rolapitant Bioequivalence Study

May 28, 2015: Heron Therapeutics Announces Positive Results from Phase 3 MAGIC Study of SUSTOL

May 20, 2015: Helsinn Group to present data on Akynzeo at 2015 ASCO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2015

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Limited, H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corporation, H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Helsinn Healthcare S.A., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics, Inc., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics, Inc., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Merck & Co., Inc., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Teikoku Pharma USA, Inc., H2 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Chemotherapy Induced Nausea and Vomiting Therapeutics - Recent Pipeline Updates, H2 2015

Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H2 2015

Chemotherapy Induced Nausea and Vomiting - Dormant Projects (Contd..1), H2 2015

Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H2 2015

Number of Products under Development for Chemotherapy Induced Nausea and Vomiting - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Acacia Pharma Limited
Aphios Corporation
Astellas Pharma Inc.
Helsinn Healthcare S.A.
Heron Therapeutics, Inc.
INSYS Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Merck & Co., Inc.
RedHill Biopharma Ltd.
SoluBest Ltd.
Suda Ltd
Teikoku Pharma USA, Inc.
Tesaro, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • Sanofi S.A.
  • Purdue Pharma L.P.
  • Almirall, S.A.